Tetrahydrobiopterin enhances regulatory T- and mast cell proliferation and alters cytokines expression in a murine heart transplant model
Authors:
- Susanne EbnerSESusanne Ebner
- Bernhard TexlerBTBernhard Texler
- Florian NardinFNFlorian Nardin
- Maria R. TroppmairMTMaria R. Troppmair
- Benno CardiniBCBenno Cardini
- Jakob TroppmairJakob Troppmair
- Georg SchäferGSGeorg Schäfer
- Gudrun C. Thalhammer-ThurnerGTGudrun C. Thalhammer-Thurner
- Katharina LacknerKLKatharina Lackner
- Natalia AleninaNANatalia Alenina
Open Access
- 16 October 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Abstract
Administration of tetrahydrobiopterin (BH4) has been shown to attenuate acute allograft rejection in a murine heart transplantation model in a manner similar to that of cyclosporine A. However, its mechanism of action on immune cells remains largely unknown. A fully MHC-mismatched (C3H/He to C57BL/6) mouse heart transplant model was used in this study. The recipients were treated with BH4 or cyclosporine A six days. The degree of acute rejection was assessed by histopathological analysis, splenocytes were analyzed by flow cytometry, and cytokine production was estimated based on the level of protein and RNA in sera and grafts and in vitro in T cell cultures. Proliferation of regulatory T cells and mast cells, suppressor capacity of Tregs, and MLR of T cells were conducted in vitro. Survival curves confirmed the significant improvement observed in the BH4-treated animals. BH4-treatment resulted in a substantial increase in Tregs and mast cells in the secondary lymphoid organs. In vitro assays showed increased proliferation of BH4-treated Tregs and mast cells. Cytokine production in vivo and in vitro in BH4-treated animals revealed an increase in the expression of IL-10, IL-5 and IL-4. BH4-dependent mast cell-derived tryptophan hydroxylase-1 could be excluded as a treatment target in recipient knockout mice. These data suggest that BH4 modulates the innate and adaptive immune systems, resulting in increased proliferation of regulatory T and mast cells accompanied by a modulation of anti-inflammatory cytokines.Keywords
All Related Versions
Funding Information
- Landes Tirols (UNI-0404/1956)
This publication has 75 references indexed in Scilit:
- IL-10 Is Required for Regulatory T Cells to Mediate Tolerance to Alloantigens In VivoThe Journal of Immunology, 2001
- ISLET ALLOGRAFT REJECTION CAN BE MEDIATED BY CD4+, ALLOANTIGEN EXPERIENCED, DIRECT PATHWAY T CELLS OF TH1 AND TH2 CYTOKINE PHENOTYPE1Transplantation, 2000
- Regulatory Role of Th-2 Cytokines, IL-10 and IL-4, in Cardiac Allograft RejectionExperimental and Molecular Pathology, 2000
- IL-10/Fc INHIBITS MACROPHAGE FUNCTION AND PROLONGS PANCREATIC ISLET XENOGRAFT SURVIVAL1Transplantation, 1999
- INDUCTION OF SPECIFIC TOLERANCE TO ALLOGRAFTS IN RATS BY THERAPY WITH NON-MITOGENIC, NON-DEPLETING ANTI-CD3 MONOCLONAL ANTIBODYTransplantation, 1999
- ARE Th2 HELPER T LYMPHOCYTES BENEFICIAL, DELETERIOUS, OR IRRELEVANT IN PROMOTING ALLOGRAFT SURVIVAL?1Transplantation, 1997
- The Th1/Th2 paradigm and the allograft responseCurrent Opinion in Immunology, 1996
- In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection.1995
- LOCAL PRODUCTION OF CYTOKINES IN THE HUMAN CARDIAC ALLOGRAFTTransplantation, 1994
- Analysis of reduced forms of biopterin in biological tissues and fluidsAnalytical Biochemistry, 1980